Expert review of hematology · 2022
Overexpression of cancerous inhibitor ofPP2A (CIP2A) in acute myeloid leukemia.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Hasanin Reem, Mossallam Ghada, Elfishawi Sally, Rabea Ahmed, Hamdy Nayera
Аннотация
BACKGROUND: Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy. Protein phosphatase 2A Protein phosphatase 2A (PP2A) is a major serine/threonine phosphatase and tumor suppressor that negatively regulates numerous signal transduction pathways. Cancerous inhibitor of PP2A (CIP2A) is an endogenous inhibitor of PP2A. CIP2A overexpression was shown to be a recurrent event in cytogenetic normal AML patients. The aim of the study is to evaluate the prognostic significance of CIP2A overexpression in patients with AML.
RESEARCH DESIGN AND METHODS: The study included 174 newly diagnosed cytogenetic normal AML patients. Detection of CIP2A expression was performed using quantitative real-time PCR.
RESULTS: CIP2A was overexpressed in 125/174 (71.8%) of patients. Correlation of CIP2A overexpression with other prognostic factors showed significant association with CD34 expression (p = 0.04). CIP2A overexpression was significantly associated with a lower rate of (complete remission) CR (p = 0.019) and shorter disease free survival (DFS) and overall survival (OS) (p < 0.001 and <0.001, respectively). In multivariate analysis, CIP2A overexpression was an independent adverse prognostic factor that negatively affected DFS and OS (p < 0.001, HR:2.8,95%CI:1.7-4.7 and p = 0.002, HR:1.8; 95%CI:1.2-2.65, respectively).
CONCLUSION: CIP2A overexpression is a useful prognostic marker in AML.
RESEARCH DESIGN AND METHODS: The study included 174 newly diagnosed cytogenetic normal AML patients. Detection of CIP2A expression was performed using quantitative real-time PCR.
RESULTS: CIP2A was overexpressed in 125/174 (71.8%) of patients. Correlation of CIP2A overexpression with other prognostic factors showed significant association with CD34 expression (p = 0.04). CIP2A overexpression was significantly associated with a lower rate of (complete remission) CR (p = 0.019) and shorter disease free survival (DFS) and overall survival (OS) (p < 0.001 and <0.001, respectively). In multivariate analysis, CIP2A overexpression was an independent adverse prognostic factor that negatively affected DFS and OS (p < 0.001, HR:2.8,95%CI:1.7-4.7 and p = 0.002, HR:1.8; 95%CI:1.2-2.65, respectively).
CONCLUSION: CIP2A overexpression is a useful prognostic marker in AML.